Kiniksa Pharmaceuticals International, plc (0001730430) recently submitted a 15-15D/A form to the Securities and Exchange Commission, signifying a significant event for the company. This type of filing is typically used to amend a previously filed 15-15D form, which is a notification of termination of registration under Section 12(g) or suspension of duty to file reports under Section 13 and 15(d) of the Securities Exchange Act.
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing and commercializing therapies for patients suffering from debilitating diseases with significant unmet medical needs. The company’s innovative approach to drug development has positioned it as a key player in the healthcare industry, with a strong pipeline of potential treatments in various stages of development. For more information about Kiniksa Pharmaceuticals International, plc, visit their website at https://www.kiniksa.com/.
Read More:
Kiniksa Pharmaceuticals International, plc Files Form 15-15D/A with the SEC
Leave a Reply